STO-609 has been widely used to examine the roles of CaMKK-mediated signaling in normal and pathophysiological conditions, including protection against prostate and liver cancers [105,106] and nonalcoholic fatty acid disease (NAFLD) [107]. The gene discussed is CAMKK2; the disease is liver cancer.